Photo = Yonhap News
The World Health Organization (WHO) issued an emergency approval decision for the new coronavirus infection (Corona 19) vaccine of Johnson & Johnson (J&J) in the United States on the 12th (local time).
The WHO made a statement that day and said, “The Corona 19 vaccine developed by J&J’s subsidiary Janssen has been put on the list for emergency use approval. The large-scale clinical trial data shared by this company shows that this vaccine is also effective for the elderly.” .
The WHO explained that the decision was based on the recommendation of the European Medicines Agency (EMA) the previous day for approval. “To expedite the process of putting this vaccine on the (emergency use) list, the WHO and evaluation teams in all regions have adopted a so-called’short form evaluation’ based on the results of the EMA review,” the WHO said.
The day before, EMA recommended approval for conditional marketing use of the Corona 19 vaccine, J&J’s European subsidiary, for those over 18 years of age.
The J&J vaccine should be stored at -20 degrees Celsius, but can be maintained for 3 months at 2-8 degrees of imaging. The shelf life is 2 years. Unlike most vaccines that require two doses, the J&J vaccine is characterized in that it can produce a preventive effect with just one dose.
WHO explained, “We have reserved 500 million doses of J&J vaccines for the COVAX facility, an international project for joint purchase and distribution of Corona 19 vaccines.” The WHO granted emergency approval for the vaccines of Pfizer and Bioentech and AstraZeneca and Oxford University vaccines produced in Korea (SK Bioscience) and India.
Hankyung.com reporter Kim Hana [email protected]
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution